Oncology Intelligence: Thoracic & Head and Neck

This week: Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.; Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.; Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.; KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer.; Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study.; Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.. A quick note: the voices you’re hearing are AI-generated. The stories are selected and edited by Dr. Rafael Santana-Davila. For healthcare professionals; not medical advice.

Latest digest: https://oncdigest.com/lung/latest
Subscribe: https://oncdigest.com/subscribe

This week: DeLLphi-305: tarlatamab added to durvalumab maintenance nearly doubles overall survival in extensive-stage SCLC, and the fight shifts to access and sequencing; FLAURA2 ctDNA analysis and PACE-LUNG: early EGFR clearance is prognostic, not predictive, so it cannot be used to skip chemotherapy; PERSEE: adding chemotherapy to pembrolizumab in PD-L1 ≥50% NSCLC more than doubles PFS, and reopens whether pembrolizumab monotherapy is a fair control arm; SAFFRON makes osimertinib plus savolitinib a chemotherapy-free standard after osimertinib progression in MET-overexpressed/amplified EGFR-mutant NSCLC; Krascendo 1: divarasib beats sotorasib/adagrasib head-to-head on PFS and OS, but the absent crossover and sotorasib-heavy control arm draw fire; OptiTROP-Lung06: sac-TMT plus pembrolizumab triples PFS versus chemo-pembrolizumab in PD-L1-negative nonsquamous NSCLC. A quick note: the voices you’re hearing are AI-generated. The stories are selected and edited by Dr. Rafael Santana-Davila. For healthcare professionals; not medical advice.

Latest digest: https://oncdigest.com/lung/latest
Subscribe: https://oncdigest.com/subscribe

Start here: what this show is, where it came from, and how papers and posts become each week's episode.

Curated by Rafael Santana-Davila, MD, a thoracic oncologist in Seattle, who picks the stories and reviews every script. For healthcare professionals. Not medical advice. No industry funding.

Latest digest: https://oncdigest.com/lung/latest

Subscribe: https://oncdigest.com/subscribe

Buy Rafael a coffee: https://buymeacoffee.com/wimhmgppax

The hosts are AI-generated voices. For healthcare professionals; not medical advice.